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AbstrACt
Introduction In older adults, dementia and depression are 
associated with individual distress and high societal costs. 
Music interventions such as group music therapy (GMT) 
and recreational choir singing (RCS) have shown promising 
effects, but their comparative effectiveness across clinical 
subgroups is unknown. This trial aims to determine 
effectiveness of GMT, RCS and their combination for care 
home residents and to examine heterogeneity of treatment 
effects across subgroups.
Methods and analysis This large, pragmatic, 
multinational cluster-randomised controlled trial with a 
2×2 factorial design will compare the effects of GMT, RCS, 
both or neither, for care home residents aged 65 years or 
older with dementia and depressive symptoms. We will 
randomise 100 care home units with ≥1000 residents 
in total across eight countries. Each intervention will be 
offered for 6 months (3 months 2 times/week followed by 
3 months 1 time/week), with extension allowed if locally 
available. The primary outcome will be the change in the 
Montgomery-Åsberg Depression Rating Scale score at 
6 months. Secondary outcomes will include depressive 
symptoms, cognitive functioning, neuropsychiatric 
symptoms, psychotropic drug use, caregiver burden, 
quality of life, mortality and costs over at least 12 months. 
The study has 90% power to detect main effects and is 
also powered to determine interaction effects with gender, 
severity and socioeconomic status.
Ethics and dissemination Ethical approval has been 
obtained for one country and will be obtained for all 
countries. Results will be presented at national and 
international conferences and published in scientific 
journals.
trial registration numbers NCT03496675; Pre-results, 
ACTRN12618000156280.
IntroduCtIon   
Dementia and depression are highly preva-
lent and comorbid conditions in older adults 
and are associated with individual distress 
and high and rising societal costs. Globally, 
around 50 million people were living with 
dementia in 2017. This number is predicted 
to reach 82 million in 2030 and 152 million 
in 2050.1 The societal costs of dementia are 
increasing from a total estimated worldwide 
amount of US$818 billion in 2015, about 
1.1% of global gross domestic product,1 to 
US$1 trillion in 2018.2 Further, the disease’s 
ramifications for families and carers are 
significant with respect to financial outlay 
and carer burden.3 Dementia is highly prev-
alent among care home residents; more than 
strengths and limitations of this study
 ► As a multinational trial, this study will provide in-
ternationally generalisable results concerning the 
effects of music interventions in older adults with 
dementia and depression.
 ► Based on previous small-scale studies, this trial will 
have adequate power to determine clinical effects 
as well as to explain variation in treatment effects in 
relation to patient characteristics.
 ► A comprehensive set of core outcomes will be mea-
sured, including long-term effects in key variables, 
with assessor blinding where relevant.
 ► The trial will also enable modelling of trajectories 
of change and will thereby contribute to an im-
proved understanding of the mechanisms of music 
interventions.
 ► Limitations include the potential bias inherent in 
cluster-randomised studies if recruitment within 
clusters is incomplete. Due to the nature of the in-
tervention, care providers and participants cannot 
be blinded, which may bias measures that rely on 
their reports.
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half of all Australian care home residents in 2016–2017 
had dementia.4 
Depression is the leading cause of disability worldwide.5 
In older adults, it co-occurs and interacts with dementia 
in complex ways. Depression can cause cognitive impair-
ment and may increase the risk of developing dementia6 7; 
conversely, depression is very common in the early stages 
of dementia6 and often exacerbated by admission to a 
long-term care facility.8 Psychotropic medication is only 
a second-line intervention due to limited efficacy and 
severe adverse effects, including increased mortality from 
antipsychotics,9 but is in practice often used to reduce 
challenging behaviours in later stages of dementia. 
Non-pharmacological interventions are available and 
have some supporting evidence, but further research is 
needed.10 Among the most promising non-pharmacolog-
ical approaches to depression and dementia are music 
interventions, and in the following section we scope out 
this evidence.
Music interventions for older adults are based on the 
notion that music elicits emotional responses and helps 
to retrieve memories,11 with recent support from research 
suggesting that brain regions responsible for processing 
music, particularly known familiar songs, may be spared 
even in late-stage dementia.12 13 They are offered in indi-
vidual,14 15 group,16 17 and community settings18
and range from targeted clinical interventions offered 
by trained music therapists to broader recreational activ-
ities, which may be facilitated by choir leaders or nursing 
staff. However, overlaps between the levels of targeting 
and training do exist. The most common group-based 
music interventions may be described as group music 
therapy (GMT) and recreational choir singing (RCS), 
where GMT is offered by a music therapist and may 
use a variety of activities ranging from singing through 
instrumental music making to music listening, whereas 
RCS is often facilitated by a choir leader and focuses 
centrally on singing. Putative mechanisms of GMT and 
RCS can be described as a combination of biological, 
psychological (cognitive and emotional) and social mech-
anisms (figure 1, left part), however with strong overlaps:
 ► Among the psychological mechanisms, emotional processing, 
such as using musical interactions to regulate affects 
and to reflect on relationships, may be most impor-
tant in GMT, but is also present to some extent in RCS. 
Cognitive processing, for example, through learning and 
memorising music pieces, is a central mechanism in 
RCS and less pronounced in GMT, although this may 
vary between cases, groups or therapists.16 19 20
 ► Social mechanisms are important in both GMT and 
RCS. The function of the group in itself may be rela-
tively more important in RCS, whereas GMT to a 
greater extent also relies on the one-to-one relation-
ship between the therapist and each group member. 
Another important part of the social mechanisms is 
developing a shared sense of mastery and achieve-
ment through learning and performing music pieces, 
which is more central in RCS than in GMT but may 
again vary from case to case.21
 ► Biological mechanisms include physical training effects 
of singing and other music-related activities, which 
may include movement. They are important in both 
GMT and RCS but may be more central in RCS.18 22
Systematic reviews of the clinical effects of GMT and 
RCS have reported mixed results,10 17 19 20 23–27 possibly 
owing to the heterogeneity of treatment effects across 
types of participants and music interventions. One small 
trial comparing GMT and RCS directly suggested that 
the comparative effects of these music interventions may 
depend on the comorbidity of dementia and depressive 
Figure 1 Mechanisms and outcomes of GMT and RCS. GMT, group music therapy; RCS, recreational choir singing.
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symptoms.16 Process-outcome relations of music interven-
tions may be described as follows (figure 1, right part):
 ► Emotional processing in a therapist-client relationship 
may lead to finding meaning and regaining orien-
tation and thereby to reduced agitation and related 
neuropsychiatric symptoms. Such effects have been 
suggested in some systematic reviews,17 26 but not 
in others.19 Reduced agitation may in consequence 
reduce burden on staff15 and consequently sick leave. 
This may also help to reduce inappropriate use of 
medication14 which is a concern in care homes.28
 ► Cognitive processing through practising music may 
promote or maintain cognitive functioning in older 
adults. Such effects have been shown for active music 
therapy, but not music listening, for people with 
dementia.20
 ► Emotional processing, but also social, biological and 
cognitive mechanisms may be associated with 
improved mood and reduced depressive symptoms. 
Systematic reviews have suggested effects of music 
therapy on depressive symptoms in older adults in 
general29 and in people with dementia.19
 ► As downstream outcomes of all four mechanisms and 
of the intermediate outcomes above, one may expect 
improved quality of life, and possibly reduced mortality, 
although these effects may be small30 31 and indirect.9 
Music interventions may also reduce costs by reducing 
time spent on treating neuropsychiatric symptoms 
and reducing absence by staff.
Hypotheses
Through these different pathways of GMT and RCS, 
one may hypothesise differential effects for different 
outcomes, and therefore for different subgroups of care 
home residents. Specifically:
 ► GMT may be more effective than no GMT, and RCS 
may be more effective than no RCS, with respect to 
reducing depression symptoms and other outcomes 
shown in figure 1.
 ► GMT and RCS may differ in the pattern of effects 
across outcome domains, which may be explained by 
their different mechanisms. For example, GMT may 
be more effective than RCS for reducing aggression 
and agitation and may therefore be more beneficial 
for people with late-stage dementia who often present 
with these neuropsychiatric symptoms.32 33 RCS may 
be more effective than GMT with respect to cognitive 
functioning. Effects on depression symptoms may be 
achieved through different pathways (figure 1), and 
the strength of those effects may therefore depend on 
severity or comorbidity.16
 ► When offered together, synergistic effects of GMT 
and RCS may occur through activation of different 
pathways.
 ► Cost-effectiveness may differ accordingly across inter-
ventions and subgroups. As RCS is likely to be associ-
ated with lower intervention costs, it may have better 
cost-effectiveness ratio in areas where clinical effects 
are similar; however, this will depend also on each 
intervention’s effects on use of other treatments and 
services.
MEtHods And AnAlysIs
design
This large, multinational cluster-randomised controlled 
trial will be conducted in care homes in Australia, 
Denmark, Germany, Italy, Netherlands, Norway, 
Poland and the UK. The list of study sites is provided 
in the trial registration record. Music Interventions for 
Dementia and Depression in ELderly care (MIDDEL) 
uses a 2×2 factorial design to examine the effects of 
GMT, RCS, both or neither, for elderly care home 
residents with dementia and depressive symptoms 
(figure 2). This design enables investigating the effects 
of two music interventions as well as potential synergy 
effects between them. These may occur between inter-
vention providers on the cluster level (GMT and RCS 
providers learning from each other) and through resi-
dents on the individual or cluster level (participants 
gaining in different ways from the combination). We 
will randomise 100 or more care home units (clusters) 
in eight countries for a total of 1000 or more partici-
pants. Recruitment started in July 2018, and primary 
completion is anticipated for April 2020.
Block randomisation (block size four clusters) will be 
used to ensure that each site will have a balanced distribu-
tion between the interventions. The computer-generated 
randomisation list will be created and kept concealed at 
the central study office. Only after the eligibility of a care 
home unit is confirmed and eligible participants (resi-
dents and staff) within that unit have formally consented 
and completed baseline assessment, will site investigators 
be informed of the randomisation result for that unit. 
Where possible, a number of care home units will be 
randomised at the same time, which will further ensure 
allocation concealment.
Blinding will be difficult to achieve. Intervention 
providers and study participants cannot be blinded to the 
intervention they receive or provide. However, partici-
pants may be unaware of the specific differences between 
GMT and RCS. Plain language summaries and consent 
forms will use neutral wording to maintain equipoise 
and to avoid expectancy effects. Blinding of assessors 
(those evaluating outcomes) will be attempted by using 
assessors external to the care homes, but this may be 
incomplete because they will have to rely on information 
from proxy informants (care staff who know the partici-
pant well) due to the inability of most residents to report 
on themselves. Assessors will remind informants not to 
reveal the unit’s allocation to them. At the time of the last 
assessment, success of blinding will be verified by asking 
assessors whether they inadvertently discovered the unit’s 
allocation.
GMT and RCS may entail ‘ripple effects’ beyond the 
individual participants by leading to changes of the local 
milieu/culture at the care home unit.15 34 These will be 
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assessed by measuring objective and perceived burden 
on care staff. The cluster design is ideally suited for that 
situation because it facilitates application in a naturalistic 
setting and avoids some of the problems of individually 
randomised trials (such as treatment contamination); 
it also minimises the additional workload for care staff. 
Trial procedures will be tested in the Australian cohort 
before applying them in the other countries. The trial will 
Figure 2 Flow of participants through the study: illustration of the study design. CDR, Clinical Dementia Rating; GMT, group 
music therapy; ICD, International Classification of Diseases and Related Health Problems; MADRS, Montgomery-Åsberg 
Depression Rating Scale; MMSE, Mini-Mental State Examination; MT, music therapy; RCS, recreational choir singing.
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be conducted and reported in accordance with relevant 
legal frameworks and research guidelines.35–38
Participants
Eligibility is defined on two levels, care home units and 
individual participants. Participating care home units will 
be those that are expected to have at least 10 eligible and 
consenting residents. Care home units that are currently 
providing music-based interventions as part of their usual 
care programme will be excluded. Eligible participants 
will meet all of the following inclusion criteria:
 ► Aged 65 years or older, resident (full-time, 24 hours/
day) at a participating care home.
 ► Dementia as indicated by a Clinical Dementia 
Rating (CDR) score of 0.5 to 2 and a Mini-Mental 
State Examination (MMSE) score of 26 or less.
 ► At least mild depressive symptoms, as indicated 
by a Montgomery-Åsberg Depression Rating Scale 
(MADRS) score of at least 8.
 ► A clinical diagnosis of dementia according to the Inter-
national Classification of Diseases and Related Health 
Problems (ICD) 10 research criteria.
 ► Have given written informed consent (maybe 
assent by proxy for those unable to provide consent 
themselves).
Clinical diagnosis will be ascertained by a clinician 
or researcher, based on the ICD-10 dementia criteria 
of memory decline; decline in other cognitive abilities; 
impairment in activities of daily living; preserved aware-
ness of the environment; decline in emotional control or 
motivation or change in social behaviour; and more than 
6-month duration of memory decline and other cogni-
tive symptoms.39 People with a known diagnosis of schizo-
phrenia or Parkinson’s disease or those who are known to 
be severely hearing-impaired, in short-term care or unable 
to tolerate sitting in a chair for at least part of the sessions, 
will be excluded. People may however have other clinical 
diagnoses such as pre-morbid substance use disorders or 
anxiety disorders. The list of exclusion criteria is inten-
tionally short to ensure generalisability.38 Residents will 
always be provided information about the study, and their 
ability for consent will be assessed directly, before turning 
to proxies (next of kin/legal representative/carer) for 
written informed assent. In case of doubt, consent/assent 
will be provided by both resident and proxy. Residents 
unable to provide written consent will still be asked if they 
agree to the interventions and assessments when these 
begin.40
Interventions
Units in all intervention arms will continue with standard 
care as locally available. In the units allocated to music 
interventions, GMT, RCS or both will be provided twice 
weekly for the first 3 months, followed by weekly sessions 
for the next 3 months. Continuation of GMT and RCS 
is allowed after that period, depending on local avail-
ability. Data on the resources related to the interventions 
will be measured (number of sessions attended by each 
participant, duration of each session, non-contact time 
spent by the intervention provider to prepare or follow-up 
a session, recorded by the provider). The components 
of standard care provided will also be recorded (see the 
Outcomes section).
GMT and RCS sessions will be 45 min each. In line with 
usual practice, GMT may be divided into smaller groups 
(eg, around five participants, but this may differ across 
local contexts), whereas RCS may be conducted in larger 
groups (eg, with all residents of the unit in one group).
Group music therapy
A core principle of GMT is affect regulation through 
active, reciprocal music making with the use of singing 
and musical instruments (table 1). This facilitates the 
relationship between the music therapist and the person 
living with dementia, and between participants in the 
group. Another core principle of GMT is to meet the 
psychosocial needs of each individual resident, which 
in turn is thought to reduce depressive symptoms and 
anxiety and to stimulate overall social and emotional well-
being.41–43 GMT aims to work in the ‘here and now’ by 
responding to participants’ immediate emotional expres-
sions, containing them and incorporating them into 
meaningful musical expressions for therapeutic gain.21 
GMT is provided by a trained music therapist, who is 
registered with the appropriate professional association 
or registration body in his or her country and should also 
be skilled as a musician. To facilitate individual relation-
ship-building, the music therapist will offer each resident 
an initial 20 min assessment with the aim of determining 
their musical preferences and starting to build individual 
rapport. The music therapist will also use other sources to 
determine the participants’ musical biography, cultural 
background, history, personal strengths, resources and 
disabilities, and any other information that could be 
useful to bring into GMT sessions.
Recreational choir singing
A core principle of RCS is to sing familiar songs and to 
provide a familiar musical environment for participants 
(table 1). Choral singing involves a combination of cogni-
tive, physical and psychosocial engagement components.44 
Drawing on the psychosocial aspects of a choir setting, 
RCS in this trial aims to foster connectedness in a group 
either with other older adults residing in the care homes 
or family caregivers; emotional well-being; and enjoyment 
of music-making in a group. Biographically and culturally 
grounded song materials are used with the central goal 
of stimulating positive experiences shared by groups of 
individuals. Where participants have engaged in music 
activities in their past, this may also enable the continu-
ation, as far as possible, of the familiar social experience 
of music-making in everyday life. Sections of RCS sessions 
may vary in their focus; for example, sessions may focus 
on developing familiarity with well-known songs; learning 
and developing new material as a group; singing rounds 
to encourage listening to each other; or offering space for 
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solo singing.45 The materials can be familiar songs from 
a range of repertoires, including but not restricted to 
festive songs (eg, birthday songs, Christmas carols), folk 
songs, traditional, classical or popular songs. The selec-
tion of songs can vary from country to country, within and 
between choir leaders, and may also depend on seasonal 
and other circumstantial factors. RCS is provided by a 
skilled musician with choir leading skills.
Training and assessment of treatment fidelity
GMT and RCS providers will receive training and imple-
ment intervention guidelines developed in the initial 
phase of the study. Regular exchange and peer super-
vision for GMT and RCS providers will be organised 
in conjunction with guidelines and training. This will 
include monthly online or in-person meetings between 
researchers and intervention providers to ensure inter-
vention quality and fidelity, to discuss potential threats 
that might undermine study quality and to refine the 
guidelines accordingly. Intervention providers will also 
attend weekly staff meetings at intervention sites where 
possible, to maximise local knowledge transfer and 
benefit. Manuals for complex interventions need to 
standardise the quality of interventions to avoid unwar-
ranted variation between therapists and countries while 
preserving the possibility for meaningful tailoring to 
local contexts and individuals.46 This will be addressed 
by focusing on general principles rather than fixed 
behaviours. Both GMT and RCS should be tailored 
to fit the current situation/status of the group and its 
individual members. Interventionists will be trained at 
all sites, both through local in-person meetings with all 
intervention providers at each site and through remote 
online training across sites. The purpose of this training 
is to supplement rather than replace the existing training 
and expertise of intervention providers. For assessment 
of adherence and competence, providers of GMT and 
RCS will be video-recorded in 3–4 randomly selected 
sessions per unit. We will record and analyse the entire 
session. To avoid performance bias due to the awareness 
of being videotaped in a selected session, we will use 
sham video monitoring in other sessions where possible. 
Videos will be uploaded and stored on a secure central 
server and will be available only to those who check treat-
ment fidelity. Two independent researchers will assess 
the different components used by intervention providers 
and the degree of person-centredness (ie, tailoring of the 
intervention to the current situation/needs of the group 
and its members). This process-related data will help us 
to understand the mechanisms or effective ingredients of 
each intervention.
Further development
While the description above provides general guidance 
and will form the basis for fidelity assessment in this study, 
no consensus guidelines exist for GMT and RCS. Descrip-
tions in the literature vary in many aspects such as: theo-
retical frame; session structure; specific therapeutic goals; 
types of musical instruments and materials; inclusion of 
music listening in addition to active music-making; struc-
tured versus improvisational techniques in active music-
making; and adaptation/tailoring to reach each person 
individually. Therefore, flexible manuals, including sets 
of detailed principles and techniques for GMT and RCS, 
will be developed and agreed on by scientific and clinical 
experts from different countries using a modified Delphi 
consensus procedure.
Table 1 Differences and similarities of group music therapy and recreational choir singing
Group music therapy Recreational choir singing
Core principles Affect regulation and attunement
Meet psychosocial needs
Empathic relationship.
Sing familiar songs, learn new songs
Cognitive activation
Focus on melody, lyrics and rhythm.
Core intentions Facilitate and improve communication.
Reduce behavioural and psychological 
symptoms through regulation of 
emotions.
Facilitate positive experience of self and 
others.
Stimulate expression, semantic 
autobiographic memory and positive 
affect.
Shared principles and intentions Use and support remaining faculty of musical reminiscence.
Tailor to individuals.
Support social experience, stimulate social and emotional well-being.
Proscribed Push participants to achieve goals. Instrumental improvisation.
Dementia inclusion criteria All levels of dementia, but may be 
divided to form homogeneous groups.
All levels of dementia, but primarily mild 
to moderately severe dementia; mixed 
groups possible (inclusiveness).
Group size Approx. 5. Approx. 10.
Qualification of intervention provider Music therapy degree; skilled musician; 
member of professional music therapy 
association or registration body.
Skilled musician, choir leading skills and 
relevant further training.
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outcomes
The study uses a broad array of resident-level, staff-level 
and unit-level outcomes measured at 3, 6 (primary) and 
12 months after randomisation (figure 3). A long-term 
extension with later follow-ups is planned separately. 
Where possible, core outcomes ( www. comet- initiative. 
org) for psychosocial intervention research in dementia 
care, that are widely used and available across the 
languages of the trial, were selected.47
The primary endpoint will be change in the total score 
of the MADRS. The MADRS is a 10-item scale where each 
item is rated from 0 (no abnormality to 6 (severe).48 In the 
Figure 3 Schedule of enrolment, interventions and assessments. CDR, Clinical Dementia Rating; CSSRI, Client Socio-
Demographic and Service Receipt Inventory; d, day; ICD, International Classification of Diseases and Related Health 
Problems; m, month; MADRS, Montgomery-Åsberg Depression Rating Scale; MMSE, Mini-Mental State Examination; NPI, 
Neuropsychiatric Inventory; PCTB, Professional Care Team Burden Scale; QOL-AD, Quality of Life-Alzheimer Disease.
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total sum score ranging from 0 to 60, higher scores indi-
cate higher severity of depressive symptoms. Assessment 
is based on an interview with the resident where possible, 
but where definite answers cannot be elicited from 
them, all relevant clues as well as information from other 
sources should be used as a basis for the rating, in line 
with usual clinical practice.49 The total time of administra-
tion is approximately 20 min. The MADRS has been used 
successfully in previous studies of music interventions.16 50 
It has shown high reliability and validity, and its sensitivity 
to change compares favourably to other scales evaluating 
depression severity in this population, such as the Cornell 
Scale for Depression in Dementia (CSDD).49 51
Secondary outcomes will include the following:
 ► Dementia severity including cognitive and func-
tional performance—CDR, a standard assessment of 
dementia severity.52 The CDR is used widely in clinical 
settings. Its score is derived from a semi-structured 
interview with the person living with dementia and an 
appropriate caregiver/relative. It rates impairment in 
each of six cognitive categories (memory, orientation, 
judgement and problem solving, community affairs, 
home and hobbies, and personal care). Its score is 
useful for characterising and tracking a person’s level 
of impairment or dementia: 0=normal; 0.5=very mild 
or questionable dementia; 1=mild dementia; 
2=moderate dementia; 3=severe dementia.
 ► Neuropsychiatric symptoms—Neuropsychiatric 
Inventory (NPI), ‘a de facto standard for measuring 
neuropsychiatric symptoms in clinical trials’.47 
Developed to assess behaviour in people living with 
dementia, the NPI has substantial evidence of validity 
and reliability and has been translated into more than 
40 languages.53 54 The NPI uses a screening approach to 
minimise administration time, examining and scoring 
only the domains with positive responses to screening 
questions. In this study, the NPI–Questionnaire (NPI-
Q)55 will be used; another version specific for nursing 
homes was considered but rejected because it is not 
available across all languages. The NPI-Q includes 
12 domains where if a symptom is present, both its 
severity (from 1=mild to 3=severe) and the associated 
distress on caregivers (from 0=not distressing at all to 
5=extreme or very severe) are assessed by the profes-
sional carer who is most familiar with the resident’s 
behaviour. Item scores across the 12 domains are 
summed, leading to a total severity score from 0 to 
36, where higher values represent higher severity. The 
additional total distress score can range from 0 to 60, 
also with higher values representing higher distress.55
 ► Generic quality of life—EuroQol (EQ-5D-5L), a 
generic health utility measure.47 The standard-
ised, non-disease-specific instrument for evaluating 
health-related quality of life was developed by the 
international EuroQol group and is used to derive 
quality-adjusted life-years (QALYs). It is based on 
a descriptive system that defines health in the five 
dimensions mobility, self-care, usual activities, pain/
discomfort and anxiety/depression. Each dimension 
has five response categories from ‘no problems’ to 
‘extreme problems’ which are combined using pref-
erence weights to form an overall quality of life score 
ranging from lower than 0 (worse than death) to 1 
(best possible). An additional visual analogue scale 
indicates today’s health on a scale from 0 (‘The worst 
health you can imagine’) to 100 (‘The best health 
you can imagine’). As most residents will be unable 
to self-rate the EQ-5D-5L, the rating will rely on the 
judgement of the carer as a proxy. Careful selection 
of assessment mode (self/proxy/both) and choice of 
appropriate proxies is important to ensure the meas-
ure’s validity in studies of people with dementia.56
 ► Disease-specific quality of life—Quality of Life in 
Alzheimer’s Dementia (QOL-AD).47 57 This 13-item 
scale with a self-rating and proxy version has demon-
strated sensitivity to psychosocial intervention, corre-
lates with health-utility measures, is widely translated 
and used internationally and can be used by people 
with very low MMSE scores. Items such as ‘Physical 
health’, ‘Memory’ or ‘Ability to do things for fun’ 
are scored on a scale from 1 (poor) to 4 (excellent), 
resulting in a total score ranging from 13 (worst) to 
52 (best).
 ► All-cause mortality (time to death), as recorded in 
official electronic registries.
 ► Any increase in psychotropic drug use: Data on type 
(Anatomical Therapeutic Chemical (ATC)Classifica-
tion System Codes N065, N06) of psychotropic medi-
cation used and any increase or decrease over time 
will be collected from care staff using the 'medica-
tion profile' section of a tailored version of the Client 
Socio-Demographic and Service Receipt Inventory 
(CSSRI).58 Available electronic health registry data 
will be used where possible. Psychotropic medica-
tions are sometimes used inappropriately to manage 
behavioural symptoms of dementia.59–61 An earlier 
study suggested that music therapy may help prevent 
increase in medication.14
 ► Costs: Total and component costs of the interventions 
will be assessed from a societal perspective, including 
the cost of the intervention as well as statutory health 
and social care services used, using a tailored version 
of the CSSRI.58
 ► Any adverse events (safety): No adverse effects of 
music interventions are known from earlier trials. 
Intervention providers are trained to work closely 
with and adapt their interventions to the needs of 
participants in order to avoid adverse reactions. 
Because little knowledge exists about what the poten-
tial adverse events could be, all types of adverse events 
and serious adverse events (eg, unexpected worsening 
of symptoms), whether related or unrelated to the 
interventions, will be reported.
Staff-level outcomes will be as follows:
 ► Subjective perceived burden of care staff: Professional 
Care Team Burden Scale.62 The 10-item scale provides 
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a valid and reliable means of obtaining ratings of 
burden from formal care teams working in care homes 
in order to evaluate different interventions targeted 
at the reduction of burden in care teams. Items are 
scored on a 5-point scale from 0 (strongly disagree) 
to 4 (strongly agree), yielding a total sum score from 
0 to 40, with higher scores indicating higher burden.
 ► Days on sick leave of care staff, as recorded monthly 
by the employer.
sample size and test power
There is no consensus on the minimal clinically important 
difference (MCID)63 on the MADRS. Generally, effect sizes 
in the small-to-medium range (ie, between d=0.20 and 
0.50) may be considered relevant.64 Effect sizes in that 
range were also found in a previous trial on GMT and RCS 
(d=0.33 at 6 weeks and 0.49 at 12 weeks).16 Studies of other 
depression scales have used anchor-based approaches to 
determine clinically important percent reductions65; we 
will not use such approaches for the primary analyses, but 
will include an additional responder analysis.63
The trial has the multiple aim of identifying main effects 
of GMT versus no GMT and RCS versus no RCS, interac-
tion effects of GMT and RCS, and predictive effects of 
clinical characteristics including severity of dementia, 
severity of depression, gender and socioeconomic differ-
ences. (Although individual socioeconomic differences 
tend to become more equal among residents in a given 
care home, they may still exist at the cluster level, as 
different homes may have different standards; we will 
use the average cost of living in each care home unit as 
a cluster-based proxy measure for socioeconomic status.) 
Power for interaction effects and subgroup analyses is 
difficult to determine because of the unknown distribu-
tions and effect sizes of the different variables. Therefore, 
the power calculation for the primary outcome was based 
on the main comparisons of GMT versus no GMT and 
RCS versus no RCS. This approach maximises power by 
fully exploiting the factorial design. A general two-sided 
significance level of 5% will be used, leading with Bonfer-
roni adjustment to a marginal two-sided level of 2.5%. 
The power calculation was adjusted for cluster effects 
using the intraclass correlation coefficient (ICC, between 
0.01 and 0.10, figure 4), assuming average cluster size 10. 
It was further assumed that attrition, which may occur 
due to death, moving to another care home or withdrawal 
from the study, will be no higher than 20% overall. With 
100 clusters and 1000 participants randomised, 90% 
power is reached for effect sizes between 0.25 and 0.35 
(figure 4). Any further increase beyond this sample size 
will serve heterogeneity of treatment effects analyses.
statistical analyses
The statistical analyses will use multivariate longitudinal 
statistical models, which make optimal use of the data by 
using data from all time points at once and can account 
for the effects of clustering within care home units and 
sites. We will use a modified intention-to-treat (ITT) 
approach using all available data from all participants 
as randomised, regardless of the intervention actually 
received. Sensitivity analyses using multiple imputation 
for missing data will enable a full ITT analysis. Additional 
per-protocol analysis will address the effects of treatments 
as actually received and will complement the ITT analyses. 
All tests in the study will be two-sided. The general signifi-
cance level is set to 0.05. Since there are two comparisons 
in the primary analysis (GMT vs no GMT, RCS vs no RCS), 
we will use a marginal Bonferroni level of 0.025. Contin-
uous variables will be screened for normality. All compu-
tations will be done using R.66
Sociodemographic and clinical baseline properties for 
the groups will be characterised by descriptive methods 
(mean [SD], median [range], n [%]) and presented in a 
table. A similar table will compare those who dropped out 
versus those who completed the primary outcome.
The primary outcome, change of MADRS score from 
baseline to 6 months, will be assessed by a linear mixed-ef-
fects model (LME).67 We will fit the unadjusted model for 
each treatment (RCS vs no RCS) as well as the multivar-
iate model containing both treatments as predictors both 
unadjusted and adjusted for the interaction between the 
treatments.
Secondary analyses of MADRS scores will include the 
following:
 ► The development of MADRS in the treatment groups 
over the entire study period will be assessed by a 
LME including time, treatment type and the interac-
tion of time and treatment type as fixed effects, and 
participant nested within cluster as random effects. 
We will use both linear and simple contrasts in the 
time domain because it is not known whether there 
is a linear association in time. This will be illustrated 
by a figure showing the predicted mean of MADRS 
for each treatment type at each time point with confi-
dence intervals.
Figure 4 Test power as a function of effect size and 
intraclass correlation coefficient (ICC). The ICC describes the 
relative similarity of participants within units and is typically 
as low as 0.05 or 0.0172; we have added the pessimistic 
scenario of ICC=0.10 for completeness only.
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 ► The synergy of the two treatments will be assessed 
by the LME containing both treatments as well as 
their interaction as predictors. The interaction in the 
model will estimate the synergy effect.
 ► The predictive effect of several covariates (severity of 
dementia, severity of depression, gender and socio-
economic differences) will be assessed as odds ratios 
using LMEs for each covariate containing time, treat-
ment type and their interaction as well as the covar-
iate and the interaction between the covariate and the 
treatment type as predictors. The interaction in the 
model will estimate the predictive effect.
Secondary endpoints will be analysed as for the primary 
analysis, using LMEs for continuous outcomes (both resi-
dent-level and staff-level). Special considerations apply 
for the following variables:
 ► Binary outcomes, including response rates (the 
proportion of residents improved by at least 50% 
from their baseline MADRS score), prevalence of 
medication use and adverse events, will be assessed 
as odds ratios using generalised linear mixed models 
(GLMMs) with a logit link function. The predictive 
effect of several covariates (severity of dementia, 
severity of depression, gender and socioeconomic 
differences) will be assessed by GLMMs for each 
covariate containing time, treatment type and their 
interaction as well as the covariate and the interac-
tion between the covariate and the treatment type as 
predictors. The interaction in the model will estimate 
the predictive effect.
 ► Count data (days of sick leave) and cost data are more 
likely to follow a Poisson distribution than a normal 
distribution and will be analysed using the respective 
GLMMs.
 ► Time-to-event data include mortality (time to death of 
any cause) and will be assessed by Kaplan-Meier and 
log-rank or Breslow tests for differences between the 
treatment types and the hazard ratios at 12 months.
 ► Loss to follow-up in all other outcomes can be influ-
enced by mortality. Thus, if the survival analysis shows 
differences between the groups, it will be meaningful 
to use a joint modelling approach which combines 
the longitudinal models and the survival analysis.68
In addition to analysing effects of interventions as 
randomised, we will conduct mediator analyses to examine 
relations between elements of the therapy approach 
(mechanisms), direct and downstream outcomes, as 
depicted in figure 1, using structural equation modelling.
Cost-effectiveness analysis
Total and component costs of the interventions and 
the cost-effectiveness of alternative interventions will be 
assessed from a societal perspective. This perspective 
will cover the cost of the intervention, statutory health 
and social care (and voluntary sector) service costs, and 
costs of unpaid carer support. The cost per session for 
each of the interventions will be derived employing estab-
lished approaches used in a compendium of costs and in 
published studies.69–71 Information on the time inputs 
by GMT and RCS providers (for running sessions and 
for other activities) will be obtained and valued using 
information on the midpoint of the salary scale and 
employer’s national insurance as well as superannuation 
contributions. The sum of the staffing contributions and 
allocations for overheads for each session will then be 
summed, to derive a cost per session. The average number 
of sessions delivered as part of the intervention will be 
multiplied to derive a cost per intervention. As there is no 
clear agreement on how the costs of group interventions 
should be allocated, we will calculate the cost per session 
of each intervention on the basis of the participants allo-
cated to each of the groups, regardless of whether or not 
the participant attended.
Data on statutory services used will be collected using 
a tailored version of the CSSRI58 which contains data on 
the use of health and other formal care resources and 
unpaid care. To service and support data we will attach 
unit costs reflecting the long-run marginal opportunity 
costs drawn from available public sources. Costs per unit 
of measurement for each service type will be taken from 
country-specific sources. We will adjust country-specific 
costs to Euros using purchasing power parity methods. 
Costs and outcomes will be compared for the compar-
ators using extended dominance approaches. In this 
approach, the four treatment combinations (GMT, RCS, 
GMT and RCS, no GMT or RCS) will be ranked by cost, 
and if one is dominated (more expensive and less effec-
tive than another), it will be excluded from further anal-
ysis, until two therapeutic groups are left on which to 
explore which of the two groups is most cost-effective. 
The cost-effectiveness of one arm over another will be 
compared by calculating incremental cost-effectiveness 
ratios defined as difference in mean costs (Euros spent) 
divided by difference in mean effects (QALYs using the 
EQ-5D-5L; points improved on MADRS and QOL-AD). 
Cost-effectiveness acceptability curves will be plotted for 
each cost-outcome combination to show the likelihood 
of one treatment being seen as cost-effective relative to 
another for a range of values placed on incremental 
outcome improvements. Using the net benefit approach, 
monetary values of incremental effects and incremental 
costs will be combined, and net benefit (NB) derived 
as: NB = λ* (effectb-effecta)–(costb–costa), where λ is 
the willingness-to-pay for a unit improvement in effec-
tiveness, and subscript ‘a’ and ‘b’ denote two candidate 
treatment arms. There is no agreed cross-national will-
ingness-to-pay threshold, and in some countries there is 
no established threshold at all. Other studies have used a 
threshold of €50 000 per QALY, and we will consider this 
in the discussion of the results.
Sensitivity analyses will be conducted to assess the 
robustness of the results to changes in key parameters. 
One of the possible concerns is likely to be the sample 
size. If the sample size in some participating countries is 
too small, their cost-effectiveness estimates are likely to be 
unreliable. We shall therefore consider the added value 
11Gold C, et al. BMJ Open 2019;9:e023436. doi:10.1136/bmjopen-2018-023436
Open access
of pooling the information on costs and outcomes in 
sensitivity analyses.
Patient and public involvement
The development of the research question and study 
design was informed by the priorities, experience and pref-
erences of residents and carers. Co-authors in Australia, 
Denmark and the UK have been actively involved in user 
and advocacy organisations in their countries for a long 
time and have discussed interventions, outcomes and the 
need for research with them. Relatives and caregivers 
spoke to the importance of music interventions as a help 
for carers and people with dementia, and to the need for 
high-quality evidence on their effects. Relatives and care-
givers are important for giving persons with dementia a 
voice when they cannot speak for themselves.
Co-authors in Australia had significant involvement 
with residents, as well as with care staff and care home 
managers, in discussing and piloting aspects of the 
study design. While the interventions were generally 
perceived as pleasurable rather than burdening, some 
of the outcome measures were felt to be burdening and 
too demanding due to their length or complexity. As a 
consequence, the longer CSDD was replaced with the 
shorter MADRS, and a more extensive quality of life scale 
was removed. Recruitment strategies were discussed and 
adapted in dialogue with care home staff.
User representatives will continue to be actively involved 
throughout the conduct of the trial (see next section). 
Results will be disseminated to residents, relatives and 
care staff via care homes. Results will also be disseminated 
to national user and advocacy organisations.
Monitoring and oversight
One representative of each recruiting institution will be a 
member in the Trial Steering Committee (TSC). They will be 
supplemented by other members who are independent of 
the investigators, their organisations, funders and spon-
sors. The TSC will include service users or their relatives 
and representatives of stakeholder organisations such as 
Alzheimer Europe and Dementia Australia. The TSC will 
have regular meetings to closely supervise all aspects of 
the study, including any protocol amendments, progress 
of recruitment and publication plan.
Data quality monitoring will require a risk-based moni-
toring approach including remote monitoring activities 
performed centrally and on-site monitoring as needed. 
The monitoring will be performed according to the 
monitoring manual to be developed at the beginning of 
the project. Recruitment and retention rates will be moni-
tored closely to mitigate the risk of slow recruitment. The 
number of participating care home units in total and 
in relation to care home units screened; the number of 
participating care home residents in total and in relation 
to residents screened of potential participants; and the 
retention of participants in the study over the trial period 
will be closely monitored.
A Data and Safety Monitoring Committee (DSMC), consisting 
of three people with strong methodological and clinical 
expertise who are not otherwise affiliated with the project 
or its institutions, will be appointed early in the interna-
tional trial. The DSMC will receive regular updates on 
recruitment, uptake of interventions, any unforeseen 
events, adverse events and immediate information on 
serious adverse events from the trial statistician. It will 
have unblinded access to study data. Meetings with the 
DSMC will be on a biannual basis and will consist of an 
open and a closed part. In the open part, the general 
progress of the trial will be discussed; in the closed part, 
the DSMC will discuss any safety signals with the trial stat-
istician. If issues arise, the DSMC will recommend to the 
TSC on appropriate action.
All aspects of the study, from intervention fidelity 
through recruitment, outcome assessment, database and 
data quality management, to data and safety monitoring, 
will be pilot-tested in one country (Australia) before being 
rolled out internationally. The data of the pilot cohort 
will be included in the main trial; no statistical adjust-
ments are made because the decision depends only on 
feasibility, not on an interim efficacy analysis. Patient-re-
lated documents such as the consent form will be tested 
because they may influence how the study is perceived by 
potential participants, relatives and staff.
To ensure data quality, a trial database will be set up and 
maintained using a safe server hosted by Uni Research 
(UHEADS) and OpenClinica software. UHEADS is a 
system for safely storing health research data developed 
by Uni Research AS, that accommodates the safe upload, 
storage and retrieval of any sensitive research data. Open-
Clinica is a web-based system for electronic data capture 
and clinical data management for multicentre clinical 
trials, which conforms to relevant international standards 
for health research. Uni Research AS runs an open source 
version of OpenClinica.
EtHICs And dIssEMInAtIon
Ethical approval has been obtained for Australia and will 
be obtained from the relevant local institutional human 
research ethics committee at each international site. Local 
clinical investigators will work on adaptation of study- and 
patient-related documentation to meet national ethical 
requirements. 
risk management
The main risks are: slow recruitment; low fidelity of inter-
ventions; and low reliability of outcome measurements. 
Regarding recruitment, we will rely on clinical investiga-
tors with a track record of successful recruitment. Slow 
recruitment at some sites can be compensated by other 
sites. Fidelity of interventions will be ensured through 
clear guidance and ongoing monitoring. Reliability of 
outcomes will be facilitated by the selection of widely 
used, recommended core outcome measures and assessed 
through tests of inter-rater reliability.
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Publication plan
The report on the main, pre-planned analyses of the 
primary endpoint and up until the 12 month follow-up 
will be submitted to a leading medical journal. The 
report on the long-term extension will also be submitted 
to a leading medical journal. Further publications may 
focus on recruitment and retention strategies for interna-
tional cluster-randomised multicentre trials of complex 
interventions in non-medical settings; development of 
an MCID for the MADRS based on an existing anchor 
question; inter-relations between outcomes and predic-
tive value of early outcomes for later outcomes; clinical 
descriptions and qualitative research of therapy processes, 
including qualitative influences on care home staff, their 
perception of GMT and RCS and their potential ‘ripple 
effects’; barriers and facilitators for implementation, 
using qualitative interviews and surveys; and consensus 
guidelines for GMT and RCS. The data and meta-data 
will be stored in a public repository, such as that of the 
Norwegian Centre for Research Data (NSD).
relevance and benefit to society
Music interventions are widely used in care homes, 
and their effects are likely heterogeneous. MIDDEL is 
designed to provide reliable and generalisable knowl-
edge about effectiveness, mechanisms and heterogeneity 
of effects of music interventions. It will also fill knowledge 
gaps about potential long-term benefits and precondi-
tions for achieving such sustained benefits. The results 
will drive changes in aged care and will contribute to our 
understanding of the relation between music and health.
Implications for practice
If MIDDEL shows beneficial effects, differences in scal-
ability need to be considered for successful implementa-
tion. GMT requires extensive, specialised music therapy 
training and is typically provided in small groups. The 
number of qualified music therapists is limited; it varies 
from country to country, but fluctuates around 1 in 100 
000 (about 6000 in Europe, http:// emtc- eu. com; 5000 in 
the USA, www. cbmt. org; 500 in Australia, www. austmta. 
org. au). RCS is more easily scalable as it can be provided 
by trained musicians and also in larger groups. There 
are about 1 million choirs and 37 million choir singers in 
Europe ( www. singingeurope. org). MIDDEL will provide 
the knowledge needed to identify the best targeting of 
both approaches, as well as contributing to their improve-
ment and standardisation. For example, GMT with its 
highly person-centred approach may be most beneficial to 
those with neuropsychiatric symptoms, which are typical 
at late-stage dementia, whereas the social engagement in 
RCS may help those at earlier stages, and the combina-
tion of both may be best for another subset of residents 
with more complex needs. The knowledge generated by 
MIDDEL will thus increase the impact of music interven-
tions in care homes and potentially in related contexts, 
such as day care centres for people still living at home.
Implications for future research
As a strongly interdisciplinary project building on contri-
butions from medicine, social sciences and humanities, 
this trial will contribute to strengthening the collabora-
tions between these fields, which is likely to stimulate new 
cross-disciplinary investigations. The study is unique in 
that it examines the interaction of depressive symptoms, 
cognitive impairment and dementia in an international 
sample of participants. A critical feature of MIDDEL is 
its attention to interventions as applied within different 
health systems. Results will be valid internationally and 
will contribute to establishing a model for future research 
within different health systems.
In conclusion, MIDDEL will provide essential knowl-
edge that will inform treatment guidelines aimed at 
improving the lives of the rapidly rising number of 
people living with dementia across countries. Building 
on previous small-scale randomised controlled trials, this 
large pragmatic effectiveness trial will enhance the use of 
health technology assessment methodology in the area of 
non-pharmacological interventions in this area. It is antic-
ipated to have a significant positive impact on people 
living with dementia, their caregivers and the health 
system. Furthermore, it will also open several new lines of 
research and development of personalised psychosocial 
interventions in an area of high and rising public health 
relevance.
Glossary of terms
 ► Site: an organisational or geographical entity 
containing several units, for example a care home/
residential care facility.
 ► Unit (or care home unit; also ‘cluster’): the smallest 
organisational unit within a site, where residents live 
together and are cared for together by staff; each unit 
is randomised.
 ► Participant: staff or residents within units who have 
consented to participate. 
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